Acute Myeloid Leukemia

Featured Article
Reviewing the Recent FDA Approval of Venclexta for AML
Tony Lin, PharmD, senior scientific director, AbbVie US medical affairs, discusses the VIALE-A and VIALE-C trials, which helped determine the approval of Venclexta for acute myeloid leukemia, and highlights what this approval means for clinical practice.
New Guidelines Address for Care of Older Adults With AML
The American Society of Hematology released new guidelines for treating older adults with acute myeloid leukemia, and recommends chemotherapy or other treatments over supportive care, along with more…
Substantial Economic Burden Accompanies Various AML Treatments
“As data for this analysis were collected before approval for these new therapies, this study serves as a baseline for the clinical and economic burden associated with AML, allowing for comparisons…

Newsfeed

Reviewing the Recent FDA Approval of Venclexta for AML
New Guidelines Address for Care of Older Adults With AML
Substantial Economic Burden Accompanies Various AML Treatments
Palliative Care Proves Beneficial in Treatment of Patients With AML
Examining Health Care Utilization, Clinical Burden of AML for Payers
Myeloablative Conditioning Improves Survival Among Patients With AML
Acute Myocardial Infarction Outcomes Worse in Patients With AML
Lower Costs, Improved Survival Linked With Nonmyeloablative Conditioning for AML
View More

Insights

Reviewing the Recent FDA Approval of Venclexta for AML
Tony Lin, PharmD, senior scientific director, AbbVie US medical affairs, discusses the VIALE-A and VIALE-C trials, which helped determine the approval of Venclexta for acute myeloid leukemia, and highlights what this approval means for clinical…
Exploring Treatment for Acute Myeloid Leukemia
AML is the most common acute leukemia in adults with an estimated 21,450 new cases expected in 2019 in the United States and approximately 10,920 deaths. In this segment, we explore various treatments for AML.
Breakthroughs in Acute Myeloid Leukemia
S Russell Spjut, PharmD, discusses current first-line therapies and new treatment opions used to treat acute myeloid leukemia and their associated costs. 
View More
Back to Top